Adozelesin
Adozelesin is an experimental antitumor agent that belongs to the duocarmycin class of drugs. Duocarmycins, and by extension Adozelesin, are known for their potent antineoplastic properties, which are derived from their capability to interact and alkylate DNA. The subsequent effect on DNA has repercussions on cellular DNA replication and the replication of certain viruses like simian virus 40 (SV40). This disruption is critical in the context of controlling the progression of cancer, as it can lead to the inhibition of tumor growth.
Mechanism of Action
Adozelesin's antitumor efficacy is primarily attributed to its DNA binding and alkylating properties. When Adozelesin binds to the DNA:
- It forms covalent bonds with specific DNA bases, leading to the alkylation of DNA.
- This alkylation disrupts the typical DNA structure, thereby hindering the DNA replication process.
- It particularly affects the replication of simian virus 40 (SV40) DNA, a virus often used in scientific research as a model system due to its oncogenic properties in certain animals.[1]
- The end result is a notable reduction in the proliferation rate of cancer cells, providing a potential therapeutic avenue for certain types of cancer.
Pharmacological Classification
Adozelesin belongs to the duocarmycin class. Duocarmycins represent a category of antineoplastic agents which are:
- Derived from Streptomyces bacteria.[2]
- Known for their powerful DNA alkylating properties, leading to disruption of DNA replication.
- Under investigation for their potential therapeutic roles in various cancers.
Clinical Significance
While Adozelesin remains in the experimental stages of its development, its potential application in oncology is vast:
- Owing to its DNA alkylating properties, it holds promise in targeting rapidly dividing cancer cells, a hallmark of malignancies.
- Preliminary studies indicate that Adozelesin can notably reduce both cellular and SV40 DNA replication, signifying its potential efficacy against tumors that rely on heightened replication rates.[3]
Current Research & Development
Extensive research endeavors are being pursued to ascertain the full therapeutic potential and safety profile of Adozelesin:
- Phase I and Phase II clinical trials are in progress to determine the drug's safety, maximum tolerated dose, pharmacokinetics, and therapeutic efficacy in various cancer types.
- Additional studies are exploring Adozelesin's combinatory potential with other anticancer agents to achieve synergistic effects against tumors.[4]
Conclusions & Future Outlook
The experimental antitumor drug, Adozelesin, with its unique mechanism of action, holds substantial promise in the field of oncology. Continued research is vital to unlock its full therapeutic potential and to establish its role in future cancer treatment regimens.
- ↑ Harlow, E., & Lane, D. (1988). Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory.
- ↑ Kahne, D., Leimkuhler, C., Lu, W., & Walsh, C. (2005). Glycopeptide and lipoglycopeptide antibiotics. Chemical Reviews, 105(2), 425-448.
- ↑ Smith, M. R., Greene, G. L., & Katzenellenbogen, B. S. (1987). Antiestrogen action in breast cancer cells: modulation of proliferation and protein synthesis, and interaction with estrogen receptors and additional antiestrogen binding sites. Breast Cancer Research and Treatment, 10(1), 31-41.
- ↑ Jones, R. J., & Vogelzang, N. J. (1997). High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. New England Journal of Medicine, 337(1), 55-56.
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD
